Our Bureau
Mumbai
It is great news for the global pharmaceutical giants Lupin Ltd. has announced that they have received approval for their Abbreviated New Drug Application for Lenalidomide Capsules within the range of 2.5 mg to 25 mg from the United States Food and Drug Administration (US FDA).
Lupin is a global pharmaceutical company that is headquartered in Mumbai, India and distributes its products in 100 different markets across the globe. The company specialises in pharmaceutical products that include branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
The Lenalidomide Capsules are used for the treatment of adult patients that are battling Multiple myeloma, in combination with dexamethasone. These new capsules will be manufactured at the Pithampur facility of Lupin in India. Both the capsules – 2.5 mg, 25 mg – had an estimated annual sale of around $7,511 million in the United States.
The pharma giant has maintained a strong position in both India and the US. It excels across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin also has 15 state-of-the-art manufacturing sites and seven research centers across the world along with that the company has a dedicated workforce of over 24,000 personnel actively working for the company.
